Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Aliment. Pharmacol. Ther.

Title: Alimentary pharmacology & therapeutics

Publisher: Wiley

ISSN (Electronic): 1365-2036

ISSN (Print): 0269-2813

Publication date (Electronic): Mar 2018

Volume: 47

Issue: 5

Affiliations

[1 ] Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo, Egypt.

[2 ] Gastroenterology and Endemic Medicine Department, Minia University, Minia, Egypt.

[3 ] Internal Medicine Department, Assuit University, Assuit, Egypt.

[4 ] Gastroenterology and Endemic Medicine Department, Ain Shams University, Cairo, Egypt.

[5 ] Rheumatology Department, Cairo University, Cairo, Egypt.

Article

DOI: 10.1111/apt.14482

PubMed ID: 29314146

SO-VID: b3f16242-8eb7-478c-a90d-0b9fae7c4c97

History

Data availability:

Comments

Comment on this article

scite_

Cited by 13

See all cited by